Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses
Yong He, Jiahui Zhou, Huizhan Gao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116069-116069
Closed Access | Times Cited: 16

Showing 16 citing articles:

DHODH inhibitors: What will it take to get them into the clinic as antivirals?
Anna Luganini, Donatella Boschi, Marco L. Lolli, et al.
Antiviral Research (2025) Vol. 236, pp. 106099-106099
Open Access | Times Cited: 1
Lipid-targeting antiviral strategies: current state and future perspectives
Ana-Belén Blázquez, Patricia Mingo‐Casas, Ernesto Quesada, et al.
Antiviral Research (2025), pp. 106103-106103
Closed Access | Times Cited: 1
Screening of Botanical Drugs Reveals the Potential Anti-human Adenovirus Activity of Berberine
Junyuan Cao, Hao Zhang, Jixiang Zhang, et al.
Antiviral Research (2025), pp. 106105-106105
Open Access | Times Cited: 1
Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment?
André Schreiber, Stephan Ludwig
Antiviral Research (2025) Vol. 235, pp. 106101-106101
Open Access
Overview of host-directed antiviral targets for future research and drug development
Xiaoxia Gu, Mengzhu Zheng, Ya Gao, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Advancing Viral Defense: Unravelling the Potential of Host-Directed Antivirals Against SARS-CoV-2
Zheng Yao Low, Siau Wui Chin, Sharifah Syed Hassan, et al.
Drugs and Drug Candidates (2025) Vol. 4, Iss. 2, pp. 13-13
Open Access
TCM theory-inspired discovery of DNJ-flavonoid conjugates as broad-spectrum anti-SARS-CoV-2 agents by primarily targeting ER-associated glycoprotein folding process
Yan‐Yun Liu, Zhaoliang Li, Yuancheng Zhou, et al.
European Journal of Medicinal Chemistry (2025), pp. 117582-117582
Closed Access
Regulation of viral replication by host restriction factors
Ying Lin, Yun Zhu, Ling Jing, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Targeting PI4KB and Src/Abl host kinases as broad-spectrum antiviral strategy: myth or real opportunity?
Maria Grazia Martina, Daniele Rubini, Marco Radi, et al.
Antiviral Research (2025) Vol. 235, pp. 106100-106100
Open Access
Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1
Maria Orfanoudaki, Lauren R. H. Krumpe, Shilpa R. Shenoy, et al.
Journal of Biological Chemistry (2025), pp. 108319-108319
Open Access
Fabrication of novel purine nucleoside derivatives bearing a cinnamic acid moiety for controlling plant viral diseases: synthesis, anti‐tobacco mosaic virus activity, and mechanistic study
Long Cheng, Xiang Zhou, Yong Huang, et al.
Pest Management Science (2025)
Closed Access
Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review
Miao Liu, Wei Peng, Xingyue Ji
Mini-Reviews in Medicinal Chemistry (2024) Vol. 25, Iss. 3, pp. 178-189
Closed Access
Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: greater similarity between humans and chickens than pigs
Mirae Kim, Chi Soo Park, Chulmin Moon, et al.
Antiviral Research (2024) Vol. 231, pp. 106009-106009
Closed Access
Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity
Thomas Shenk, John L. Kulp, Lillian W. Chiang
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1298-1298
Open Access
Discovery of novel Favipiravir derivatives with improved pharmacokinetic properties as anti-SFTSV agents
Xiaomeng He, Fan Wu, Wei Li, et al.
European Journal of Medicinal Chemistry Reports (2024), pp. 100226-100226
Open Access
Repurposing Lapatinib as a Triple Antagonist of Chemokine Receptors 3, 4 and 5
Thomas R. Lane, Ana C. Puhl, Patricia A. Vignaux, et al.
Molecular Pharmacology (2024) Vol. 107, Iss. 1, pp. 100010-100010
Closed Access
Page 1

Scroll to top